Poor
Misaligned
Patient Risk:
Medium
Summary
Several key claims (indications, mechanism, dosing interval/frequency, and “administered by a healthcare professional”) are not supported by the provided label excerpts. Some adverse reaction claims are supported (back pain, hypercholesterolemia, severe hypocalcemia, osteonecrosis of the jaw), but overall alignment is limited by multiple unsupported or uncheckable safety/dosing assertions.
Category Scores
Accurate Statements
Prolia (denosumab) is a subcutaneous injection product.
11 DESCRIPTION: "Prolia (denosumab) injection ... for subcutaneous use."
Common side effects include back pain.
6 ADVERSE REACTIONS: "The most common adverse reactions... are back pain" (postmenopausal osteoporosis).
Common side effects include elevated cholesterol levels (hypercholesterolemia).
6 ADVERSE REACTIONS: "hypercholesterolemia" listed among most common adverse reactions (postmenopausal osteoporosis).
More serious side effects may include low calcium levels (severe hypocalcemia and mineral metabolism changes).
6 ADVERSE REACTIONS: "Severe Hypocalcemia and Mineral Metabolism Changes" (serious adverse reaction).
More serious side effects may include osteonecrosis of the jaw.
6 ADVERSE REACTIONS: "Osteonecrosis of the Jaw" (serious adverse reaction).
Unsupported Statements
Prolia is a brand name for denosumab.
Partially supported: label excerpt states "Prolia (denosumab) injection" but the claim is not fully supported as a standalone brand-name mapping within the provided evidence.
Prolia is used to treat osteoporosis in postmenopausal women at high risk of fracture.
Indication text was not provided from 1 INDICATIONS AND USAGE.
Prolia is used to treat bone loss in men receiving certain cancer treatments.
No relevant indication text provided from 1 INDICATIONS AND USAGE.
Prolia is used to treat giant cell tumor of bone in certain adults and adolescents.
No relevant indication text provided from 1 INDICATIONS AND USAGE.
Prolia works by decreasing the activity of osteoclasts.
Mechanism-of-action content not provided from 12 CLINICAL PHARMACOLOGY.
Osteoclasts are responsible for breaking down bone.
No relevant content provided from 12 CLINICAL PHARMACOLOGY.
Prolia is typically administered as a subcutaneous injection every six months.
Route is supported by 11 DESCRIPTION, but dosing interval/frequency (“every six months”) is not supported because 2 DOSAGE AND ADMINISTRATION content was not provided.
Prolia is administered by a healthcare professional.
No relevant content provided from 2 DOSAGE AND ADMINISTRATION.
Common side effects can include pain in the arms or legs.
Partially supported: label excerpt mentions "pain in extremity" but does not explicitly specify arms vs legs.
Common side effects can include muscle pain.
Partially supported: label excerpt lists "musculoskeletal pain" but does not explicitly state “muscle pain.”
More serious side effects may include severe skin reactions.
The label excerpt lists "Dermatologic Adverse Reactions" as a serious adverse reaction but does not provide wording that equates this to “severe skin reactions.”
Osteonecrosis of the jaw is a condition where bone tissue dies.
No definitional statement provided in the provided label excerpts.
Contradictions
Important Omissions
No indication-specific details (exact labeled indications, eligibility criteria, or other required framing) could be verified because 1 INDICATIONS AND USAGE was not provided in the evidence.
Importance:
Moderate
No dosing administration details beyond route could be verified (e.g., dosing interval, injection volume/site, and any administration precautions) because 2 DOSAGE AND ADMINISTRATION was not provided in the evidence.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Several key safety-relevant claims related to dosing interval and administration context are not supported by the provided label excerpts, and multiple major efficacy/indication claims are unverifiable from the supplied evidence. Some serious adverse reaction categories are supported (severe hypocalcemia, osteonecrosis of the jaw), but the overall labeling alignment is insufficient for assurance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Misaligned
Primary Issue
Multiple claims are not supported by the provided FDA label excerpts, especially indications, mechanism, and dosing interval/frequency.
Suggested Improvement
Restrict claims to what is present in the provided label sections (e.g., subcutaneous route; supported adverse reaction categories) or supply the missing label sections (1 INDICATIONS AND USAGE, 2 DOSAGE AND ADMINISTRATION, 12 CLINICAL PHARMACOLOGY, and relevant definitions/warnings) to verify and accurately restate the approved prescribing information.